StockTipsArenaBeta

BUY Piramal Pharma Limited — Goldman Sachs

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)24 Sept 2026via Zee Business (Live)

Entry₹210.65Inferred
Target₹250
Total upside +18.68% (call closed)
Stop lossNot given
Exit₹2509 Nov 2026, 9:35 am
Target hit+18.68%0.00%upside left
Follow Goldman Sachs for new calls(100% target hit, 47 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 6 active Long-term calls on PPLPHARMASee 273 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Nov 2026
28 supporting10 neutral7 opposing
Supports the BUY call (28)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 Nov · 4d ago

5 other SEBI-registered advisors have active long-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·30 Oct · 1w ago

Piramal Pharma shares surge 17% as Q2 revenue rises 28.1% YoY to ₹2,617 Cr and net profit turns positive to ₹5.6 Cr

NewsGoogle News·28 Oct · 2w ago

(opens in new tab)

Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

NewsCnbc-Tv18·28 Oct · 2w ago

(opens in new tab)

Piramal Pharma Limited Announces Results for Q2 and H1 FY27

NewsGoogle News·28 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (10)

Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (7)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Goldman Sachs

Every call and its outcome